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Rome, Italy; Auckland, New Zealand; Tallinn, Estonia; Galway, Ireland; Aarhus, Denmark; and Riga, LatviaBackground Percutaneous coronary intervention in complex bifurcation lesions is prone to suboptimal implantation
results and is associated with increased risk of subsequent clinical events. Angiographic ambiguity is high during bifurcation
stenting, but it is unknown if procedural guidance by intravascular optical coherence tomography (OCT) improves clinical
outcome.
Methods and design OCTOBER is a randomized, investigator-initiated, multicenter trial aimed to show superiority
of OCT-guided stent implantation compared to standard angiographic-guided implantation in bifurcation lesions. The primary
outcome measure is a 2-year composite end point of cardiac death, target lesion myocardial infarction, and ischemia-driven
target lesion revascularization. The calculated sample size is 1,200 patients in total, and allocation is 1:1. Eligible patients
have stable or unstable angina pectoris or stabilized non–ST elevation myocardial infarction, and a coronary bifurcation lesion
with significant main vessel stenosis and more than 50 % stenosis in a side branch with a reference diameter ≥2.5mm.
Treatment is performed by the provisional side branch stenting technique or 2-stent techniques, and the systematic OCT guiding
protocol is aimed to evaluate (1) plaque preparation, (2) lesion length, (3) segmental reference sizes, (4) lesion coverage, (5)
stent expansion, (6) malapposition, (7) wire positions, and (8) ostial results.
Implications A positive outcome of the OCTOBER trial may establish OCT as a routine tool for optimization of complex
percutaneous coronary intervention, whereas a negative result would indicate that OCT remains a tool for ad hoc evaluation in
selected cases. (Am Heart J 2018;205:97-109.)Background
Complex treatment of bifurcation lesions is associated
with worse outcome than simple treatment.1,2 Guiding of
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Cardiology, Galway University Hospital, Galway, Ireland, Department of Clinicalhigh angiographic ambiguity in visualization of lesions,3
the side branch ostium,4 stent expansion,5 stent apposi-
tion,6 and wire positions critical for correct delivery of
balloons and stents.7 The lack of adequate proceduralhttps://doi.org/10.1016/j.ahj.2018.08.003l
s
,
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treatment results associated with higher risk of clinical
events during and after treatment.8-10 Intravascular
optical coherence tomography (OCT) provides visualiza-
tion of the vessel wall, vessel lumen, plaque components,
dissections, stents, and wires at a very high resolution,
enabling precise measurements and stepwise verification
and optimization during complex percutaneous coronary
intervention (PCI).7,11-13 It is unknown if routine
structured use of OCT during complex bifurcation
stenting improves clinical outcome as compared to
standard practice with angiographic guiding and optional
use of intravascular ultrasound. The OCTOBER trial aims
to demonstrate that OCT-guided PCI improves clinical
outcome as compared to standard practice.
Methods
Study design
The OCTOBER trial is an investigator-initiated, random-
ized (1:1), controlled, prospective, superiority, multicen-
ter trial with planned enrolment of 1,200 patients in 60
centers in Europe. By August 1, 2018, a total of 156
patients have been randomized. Estimated final enrol-
ment day is December 31, 2019, with reporting of
primary end point in the second half of 2021.
Notifications
The study is notified to the local or national ethics
committees as appropriate and to theDanishData Protection
Agency covering all sites within the European Union. The
trial is registered with Clinicaltrials.gov NCT03171311. Only
CE-marked equipment is used and only for approved
indications. The principles in the Declaration of Helsinki
are followed, and all patients provide written informed
consent for participation in the trial.
Patient population
Patients with stable angina pectoris, or stabilized non–
ST elevation myocardial infarction (NSTEMI) and a
significant bifurcation lesion involving a large side branch
are eligible for participation. The side branch should have
an estimated proximal reference size of at least 2.5 mm
and more than 50% diameter stenosis in the ostium by
visual estimation. All lesion lengths are allowed, and distal
segments requiring treatment are allowed to have smaller
reference size than 2.5 mm.
Complete clinical and angiographic inclusion and
exclusion criteria are listed in Figure 1.Primary end point
The composite end point of major adverse cardiac
events (MACE) includes cardiac death, target lesion
myocardial infarction (MI), and ischemia-driven target
lesion revascularization (TLR) at 2 years.Secondary composite end points
The study bifurcation-oriented composite end point
includes cardiac death, target bifurcation MI, and
ischemia-driven target bifurcation revascularization. The
patient-oriented composite end point is all-cause mortal-
ity, MI, any revascularization, and stroke. Individual
secondary end points are listed in Table I.
Treatment allocation. Patients are randomized 1:1 to
either OCT-guided revascularization or standard angiogra-
phy-guided revascularization after diagnostic coronary angi-
ography and the ability towire both branches (Figure 1). The
randomization is stratified (1) for operators’ intention to
performeither theprovisional sidebranch stenting technique
or a planned 2-stent technique and (2) for bifurcation lesion
location (left main coronary artery [LMCA] or non-LMCA). In
patients allocated to OCT guiding, all lesions for treatment
should be guided byOCT at least until the last follow-up time
point for the primary end point.
Consort patient flow documentation
Patients are enrolled according to clinical inclusion and
exclusion criteria (Figure 1), and only fully eligible
patients are randomized.Study procedure
PCI technique, both allocations. Access route and
wires are selected at the operator´s discretion. Guiding
catheters should be at least 6F, and in cases with very
large vessels and in LMCA stenting, 7F and 8F catheters
are recommended for optimal support and improved
flushing in OCT-guided cases. Recommended stent
techniques are the provisional side branch stenting
technique with mandatory kissing balloon inflation and
the 2-stent techniques: double kissing (DK) crush,
culotte, T and protrude technique, and T-stenting. Classic
crush, inverted crush, mini crush, and simultaneous
kissing stent techniques are not allowed. For all stents
implanted across a bifurcation whether from the main
vessel or the side branch, postdilatation of the stent from
the carina to the proximal stent edge according to the
reference size is mandatory and should be performed as
the first step after implantation. Kissing balloon inflation
is performed using noncompliant balloons sized 1:1 to
the SB and distal MV segments, respectively, and with (1)
sequential high-pressure balloon inflations (20 atm)
before (2) simultaneous inflation at 8-12 atm and exact
simultaneous deflation. Proximal optimization technique
(POT) after kissing balloon inflation is optional, and if
performed, it is critical that the distal balloon marker is
positioned 1-2 mm proximal to the proximal side branch
take-off spring to avoid distorting the core bifurcation
segment. Recommendations are detailed in the study
protocol, and treatment in both arms follows the
sequence and structure shown in the OCT guiding
manual (supplement).
Figure 1
Patient flowchart. AP, angina pectoris; CABG, coronary artery bypass grafting; CTO, chronic total occlusion; GFR, glomerular filtration rate; IVUS,
intravascular ultrasound; LVEF, left ventricular ejection fraction; MACE, major adverse cardiac events; MV, main vessel; SB, side branch; STEMI,
ST-elevation myocardial infarction.
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Table. Primary and secondary end points
Primary end point
• Combined end point of 2-y MACE
(cardiac death, target lesion MI, ischemia-driven TLR)
Secondary end points, clinical
• Study bifurcation-oriented end point: composite of cardiac death,
target bifurcation MI, target bifurcation revascularization
• Patient-oriented composite end point: all-cause mortality, MI, any
revascularization, stroke
• Clinical end points at 1, 12, 24, 36, 48, and 60, m:
• All-cause mortality (including 120 m)
• Cardiac death
• MI
• Stent thrombosis (definite, possible, probable)
• Target lesion MI
• TLR
• Target bifurcation MI
• Target bifurcation revascularization
• Target vessel revascularization
• Any revascularization
• CCS angina class
Secondary end points, procedural
• Contrast volume
• Procedure time
• Fluoroscopy time
• Number of stents implanted in target lesion
• Number of stents implanted in nontarget lesions
• Total stent length in target lesion
• Total stent length in total
• Procedural success (TIMI III flow and b30% diameter stenosis in target
segments by QCA)
OCT-guided group:
• Successful treatment-specific OCT acquisitions (study procedure)
• Successful final OCT acquisition in main vessel (success defined as
analyzable stented segment)
• Successful final OCT acquisition in stented site branch
Secondary end points, angiographic (3D QCA)
Target bifurcation
• Minimal luminal diameter and diameter stenosis post-PCI
○ In-segment
○ Segmental; proximal edge, proximal MV, bifurcation core
segment, distal MV ostium, distal MV, distal edge, SB ostium,
SB, SB edge
Nontarget lesions
• Luminal diameter and diameter stenosis post-PCI
○ In-segment
○ Segmental: proximal edge, in-stent, distal edge
QCA, quantitative coronary angiography; MV, main vessel; SB, side branch.; TLR,
target lesion revascularization; CCS, canadian cardiovascular society grading of
angina; TIMI, thrombolysis in myocardial infarction
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strategy is designed to achieve 3 aims: (1) adequate vessel
and stent expansion, (2) full stent apposition, and (3)
optimal lesion coverage. As OCT scans require additional
instrumentation and contrast use, balancing the number
of scans and the potential benefit has been a main focus
to ensure clinical feasibility. Of utmost importance for
feasibility is the timing of scans at specific time points
during the procedure where the chance of a successful
scan is high and where OCT may provide most useful and
clinically important information to guide the stent
implantation. As OCT provides a wealth of information,checklists for the specific scans are provided to give
priority to extraction of most important information
balanced against time consumption of in-procedure OCT
analysis. The OCT guiding protocol is detailed in the
protocol, and a short illustrated version is available for
training and in-procedure instructions (supplement). The
checklist-based guiding protocol is detailed for the
provisional side branch stenting strategy with mandatory
kissing balloon inflation and the 4 recommended 2-stent
techniques. The general structure is shown in Figure 2.
The guiding principles are as follows: (1) predilatation of
lesion segments to be stented according to angiographic
findings; (2) OCT of predilated segments for evaluation of
lesion preparation, planning stent length, and estimation
of reference diameter in segments to be stented; (3) stent
implantation, postdilatation at high pressure of all stented
segments with noncompliant (NC) balloons sized 1:1 to
the reference diameter, and rewiring of the side branch;
(4) OCT evaluation of stent expansion and apposition,
exclusion of geographical miss with residual edge
stenosis, evaluation of wire position in recrossing into
the side branch, and ruling out accidental abluminal
rewiring of proximal main vessel segments; after
correcting accordingly, (5) sequential kissing balloon
inflation followed by simultaneous kissing balloon
inflation; final POT is optional; (6) final OCT of all stented
segments for evaluation of stent expansion and apposi-
tion, and assessment of the side branch ostium; and (7)
removal of wires and final angiography in 2 projections
and high frame rate enabling core laboratory 3D QCA
analysis. The differences in sequence of steps between
the 5 stent techniques necessitate a customized approach
for each technique as outlined in the manual, but the
timing of OCT scans is the same for all techniques: (A)
after predilatation but before stent implantation, (B) after
each rewiring, and (C) the final result of all stented
segments.
Crossover and use of IVUS. Use of OCT scans in the
control arm is not allowed. Use of IVUS is not encouraged
and may not be used routinely in the control arm, but if an
operator finds it necessary to evaluate with intravascular
imaging, IVUS may be used.
Multivessel treatment. Indication for treatment of
other lesions follows present guidelines regarding docu-
mentation for ischemia producing potential. Full revas-
cularization is recommended. Treatment of other lesions
should also follow the allocation for type of guiding.
Staged procedures are allowed as long as the study
bifurcation is treated in the first index procedure. The
study allocation also applies to staged procedures.
Study stent and medical treatment (both arms).
The Xience drug-eluting stent (DES) (Chicago, Illinois,
Abbott) is the study stent and is used in all cases,
including nonstudy lesions. Before implantation, patients
are loaded with clopidogrel (300-600 mg), prasugrel (60
mg), or ticagrelor (180 mg) and aspirin (300 mg)
Figure 2
Principal structure of OCTOBER OCT guiding protocol. See supplemental information for specific OCT guiding protocols for provisional stenting
and for DK crush, T and protrude technique, T-stenting, and culotte 2-stent techniques. *Mandatory in the MV and encouraged in the SB in 2-stent
techniques, †for DK crush and culotte techniques. OCT imaging is performed using Abbott OCT-systems (Ilumien, Ilumien Optis, or Optis
integrated).
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Figure 3
Strategy for evaluation of patients with potential or manifest event. Objective evidence for lesion-specific ischemic potential is mandatory before
treatment of in-stent restenosis in patients with stable angina pectoris. OCT evaluation before treatment of stent failure is performed in patients with
possible or manifest events with both trial allocations. DS, diameter stenosis; ECG, electrocardiogram; FFR, fractional flow reserve.
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or local instructions. During the procedure, patients are
treated with heparin (activated clotting time (ACT) N250
checked every 30-60 minutes). After procedures indicat-
ed by stable angina pectoris, clopidogrel 75 mg/d is
indicated for 6 months, and after procedures indicated by
UAP or Non-ST-elevation MI (NSTEMI), prasugrel 10 mg/d
(5 mg/d if age N75 years or weight b60 kg) or ticagrelor
90 mg ×2/d is indicated for 12 months. All patients are
prescribed lifelong aspirin at 75 mg/d.
Evaluation of patients with potential or manifest
events. Figure 3 describes the algorithm for evaluation of
patients with potential or manifest events.Study training and feed back
Training and lead-in-cases. All study sites will
receive on-site training before inclusion start and are
required to have successfully performed at least 2 cases of
OCT-guided complex bifurcation treatment cases beforeentering the study. Study material, descriptive posters
with key OCT findings, and image-based study flowcharts
are provided (Figure 4 and supplement).
OCT guiding continuous feedback. Investigators
receive confidential “next day” case-by-case core labora-
tory feedback of all OCT-guided procedures throughout
the study for continuous optimization of physicians’
skills. The feedback covers the quality and procedural
timing of OCT acquisitions, measurements, and adequate
decisions but also comments on regular procedural
aspects in bifurcation stenting. An important aspect is
to increase physicians’ confidence in relying on OCT for
treatment decisions, in particular when there is mismatch
between OCT and angiographic findings.
Angiographic core laboratory analysis
Angiographic analysis is performed for all patients in both
treatment arms.The target bifurcation is analyzedby applying
a 7-segmentmodel for bifurcations and a 3-segmentmodel for
straight vessel analysis. Balloon-treated segments are analyzed
Figure 4
Setup for initiation and training of sites, and continuous OCT case feedback during enrolment.
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size, diameter stenosis %, minimal lumen diameter, lesion
length, and angulations. Thepre- andpost-PCI angiograms are
analyzed by observers blinded to the allocation. Analysis is
performed at the Interventional Imaging Core Laboratory,
Aarhus University Hospital, Denmark, using the Medis
QAngio3DXA bifurcation analysis application (MedisMedical
Imaging, the Netherlands, Leiden).OCT core laboratory analysis
OCT scans are divided into 8 subsegments: the 3 edge
segments, the proximal and distal MV, the bifurcation
core segment, the SB ostium, and the remaining SB.Prestent analysis of target bifurcation
OCT runs are analyzed for landing zone estimation,
segmental reference diameters, and minimal lumen area.
The reference diameters are measured for comparison to
in-procedure estimates following the same algorithm
(supplement). If valid reference estimation is not possible
by OCT, 3D QCA–derived reference size is used.
Poststent implantation and wire recrossing. OCT
runs are analyzed for geographical miss compared to
in-procedure indicated landing zone, position of cell
recrossing, and accidental abluminal rewiring.
Final result. OCT runs are analyzed for mean and
minimal stent and lumen area, rate of accidental crushed
stent segments, malapposition, and intraluminal masses.
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is reported.
OCT analysis is performed at the Interventional Imaging
Core Laboratory, Aarhus University Hospital, Denmark.
Sample size calculation
Estimates for median 2-year MACE rates are based on the
following evidence and assumptions. The 2-yearMACE rate
in the Syntax LMCA subgroup treated by PCI was 22.6%.
This included 1.4% cerebrovascular events. This popula-
tion also included isolated LMCA ostial andmidshaft lesion.
The DELTA registry comparing ostial/midshaft and distal
LMCA bifurcation lesions reported median 3.5-year MACE
rate of 19% and 28%, respectively.14 The 2-year MACE rate
in the MAIN COMPARE 2-stent group was 24%,15 and
MACE at mean 32months in the meta-analysis by Karrowni
et al was 20% in the single stent group versus 33% after
2-stent treatment of LMCA bifurcations.16 Patients treated
for LMCA bifurcation lesions in the Nordic Bifurcation
study III had a MACE rate of 25% at 3 years (in review). The
DKCRUSH III comparing the DK crush technique and
culotte for LMCA bifurcation treatment reported 3-year
MACE of 8.2% and 23.7%, indicating that different 2-stent
techniques may be associated with different clinical
outcome.17 Still, the utilization of intracoronary imaging
in all the studies except for MAIN COMPARE was low.15
Therefore, applying a newer-generation DES in a
population where patients require 2-stent treatment or
have increased complexity due to side branch stenosis
and with a 60% ratio of LMCA to non-LMCA bifurcations
and a 30% patient-level requirement for multivessel
stenting, we expect a 2-year event rate of approximately
16% by standard guiding (population standard).
The clinical value of using OCT to detect correctable
factors not visible by angiography during PCI is sparsely
investigated. The CLI-OPCI matched analysis found a
reduction in 1-year MACE by OCT guiding from 14.8% to
9.6% in a standard PCI population,18 and the CLI-OPCI II
registry reported that suboptimal PCI result as detected by
OCT was an independent predictor of worse outcome
(MACE hazard ratio [HR]: 3.53; 95% CI: 2.2-5.8; P b .001).19
The randomized IVUS-XPL trial byHong et al showed a 50%
reduction in MACE driven by reduction in MACE in the
IVUS guidance group but overall low 1-year event rates.20
The randomized studies by Antonsen et al21 and Jun-Sung
Kim et al22 both showed a significant improvement in
6-month stent strut coverage by OCT guiding compared to
angiographic guiding, further indicating positive effects of
OCT optimization. Complex PCI of bifurcation lesions
suffers from a high degree of angiographic ambiguity.
Therefore, we expect that the positive effects of OCT
guiding should at least be at levelwith the findings reported
in average PCI populations. We therefore estimated an
absolute reduction in 2-year MACE from 16% to 10% by
routine OCT guidance. With α = .05 and power = 80%, a
total of 984 patients (n = 492 in each group) are required.To accommodate for uncertainty of estimates and
lost-to-follow-up, the inclusion target is 1,200 patients total.
Statistics
Continuous variables are compared using the 2-sample
t test (or Welch approximation in case of unequal
variances) or the Mann-Whitney U test if data follow a
nonnormal distribution. Categorical variables are ana-
lyzed with the χ2 test or Fisher exact test if cell numbers
are small. The main effect measure is the 0- to 24-month
HRs estimated by adjusted and unadjusted Cox regression
based on intention-to-treat principle. Per-protocol analy-
ses are performed for the combined end points. The final
follow-up date for the primary end point is when median
2 years of follow-up has been reached and the last
enrolled patient has been followed for at least 1 year.
Both intention-to-treat and per protocol analyses are
performed for all composite end points. All end points are
assessed until death or loss to follow-up. Cumulative
incidence curves are plotted (treating death as nonevent).
Patients treated by the standard guiding strategy are used
as the reference group for the overall and subgroup
analyses. HR estimates for major adverse cardiac events at
24 months of follow-up are estimated for prespecified
subgroups of patients (classified by baseline demographic
and clinical characteristics). Effects of baseline differ-
ences between groups are evaluated by Cox proportio-
nal-hazard regression analysis. A 2-sided P value of less
than .05 indicates significance.
Subgroup analysis are prespecified for the following
subgroups: 1-stent techniques, 2-stent techniques, LMCA
bifurcation subgroup, single-vessel disease, multivessel
disease, long and short SB disease, optimal and subopti-
mal angiographic results, stable angina pectoris and acute
coronary syndrome (ACS), diabetes, gender, calcified
lesions, and SYNTAX score above 11 and are presented in
a forest plot.
Data collection and monitoring
Data collection, processing, and storage. Data are
entered directly in the e-CRF in the secure Web-based trial
management system, TrialPartner, Institute of Clinical
Medicine, Aarhus University Hospital. Imaging data includ-
ing angiographic image runs and all OCT scans are
uploaded to the study database, enabling remote monitor-
ing and procedure feedback by the central core laboratory.
Data regarding readmission and source data for clinical end
point committee evaluation are uploaded as well.
Monitoring of the study. The study is monitored
according to the Good Clinical Practice guidelines.
During the study period, monitors will ensure that the
trial is conducted in compliance with the protocol, Good
Clinical Practice, and applicable regulatory requirements.
The monitors perform remote and on-site reviews for
verification of consistency and correctness of recorded
data.
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Volume 205, Number 0Data Safety Monitoring Board. The safety of the
study is monitored by an independent external safety
committee (Data Safety Monitoring Board [DSMB])
headed by Juha Hartikainen, Kuopio, Finland. The
DSMB receives information on rates of death, MI, stent
thrombosis, and repeat revascularization. The DMSB
independently makes decision on continuation, pausing,
or stopping the study. Applicable ethics committees and
site PI are informed immediately of any changes in the
study risk assessment and study status.
Ethical aspects
OCT has a IIB recommendation by European Society of
Cardiology guidelines for optimizing PCI.23 The strategy
in both treatment arms is at present clinically applicable
nonstudy treatments, and it is unknown if one is
beneficial over the other. Optimization by OCT follows
established technical treatment goals, and the implanta-
tion techniques allowed in the study are recommended
standard techniques.24 The experimental aspect is the
routine use of systematic OCT guiding during invasive
angiography compared to present standard practice of
primarily angiographic guiding and unstructured ad hoc
use of invasive imaging mostly performed using IVUS.
Allocation of the guiding strategy by randomization is
therefore deemed acceptable.
Funding
The Sponsor (Aarhus University Hospital, Denmark)
has received an institutional research grant from Abbott,
USA, to conduct the study according to the protocol and
the prespecified budget and to provide participating
centers a limited milestone-based per patient payment.
Abbott did not have any influence on the study design or
protocol in any aspect. Abbott will not be involved with
the conduct of the study including training, enrolment,
follow-up, data collection, analysis, interpretation of data,
drafting, or final approval of the manuscript. The authors
are solely responsible for the design of this study the
drafting and editing of the paper and its final contents.Discussion
The purpose of the OCTOBER trial is to evaluate if
structured OCT guidance during complex bifurcation PCI
improves clinical outcome compared to PCI guided by
angiography with optional IVUS. Optimal performed
complex bifurcation stenting has been investigated and
debated intensively. The vast majority of clinical com-
parisons of stent implantation strategies in bifurcations
have focused on 1-stent treatment with and without
kissing balloon inflation, 1- versus 2-stent techniques, or
comparisons of different 2-stent strategies. The goal of
any technical strategy must be to alleviate downstream
ischemia and ensure low complication rates both during
PCI and beyond. Four principal factors may be importantin achieving this: (1) adequate lesion coverage, (2)
thorough expansion of stent and vessel, (3) avoiding
malapposition, and (4) use of best-in-class DES. Many
bifurcation stent techniques and present-generation DES
allow for fulfilment of these treatment goals. Still, acute
results after complex bifurcation stenting are highly
sensitive to optimal sizing of stents and balloons, as well
as the sequence of implantation steps and balloon
dilatations. Angiographic ambiguity is high during com-
plex bifurcation PCI, and IVUS interpretation in this
setting is nontrivial for most interventional cardiologists.
The OCT treatment protocol is based on the following:
Full lesion coverage
After introduction of first-generation DES with low late
lumen loss, full lesion coverage was a widely accepted
treatment strategy until it was shown that longer stented
segments and overlapping stents were associated with
increased risk of periprocedural MI, restenosis, and stent
thrombosis.25,26 So-called spot stenting was advocated,
aiming for treatment of most flow-limiting sections only.27
This in turn led to high rates of edge restenosis.28
Second-generation DES did not show the same risk
associated with overlapping and implanting of longer
stents.29 Kang et al showed that plaque burden N55% but
not lumen diameter in the stent edge after implantation of
second-generation DES predicted edge restenosis.30 OCT
has the potential to identify the extent of the lesion before
stent implantation to allowplanned full lesion coverage and
potentially lower the risk of geographical miss.11,12,31
Consequently, OCT-guided full lesion coverage is intended
in the OCTOBER trial. After identifying the intended stent
landing zones, OCT enables evaluation of the actual stent
landing zone based on available stent lengths and PCI
technical requirements before implanting the stents. Use of
angio-OCT co-registration may improve precision and
feasibility during stent sizing and positioning, and is
recommended. When the stent is implanted, the OCT
evaluation of edge segments may reveal if the intended
landing zone was covered and if residual stenosis, major
plaques, dissection, or plaque rupture is present. The
principles for lesion coverage are further based on the
CLI-OPCI trial that identified residual edge stenosis as a
strong predictor of MACE and on the IVUS edge dissection
trials showing that edge dissections visible by angiography
was associated with increased MACE.18,32,33
Stent expansion
Underexpansion of stented segments is associated with
in-stent restenosis34,35 and is a frequent finding after
otherwise apparent successful angiographic-guided stent
implantation.36,37 Kang et al (2011) showed that segmen-
tal cutoff values for minimal luminal area in the distal left
main bifurcation predicted TLR.38 These values may
become the standard of care but are only used
sporadically, and the assessment of the circumflex (Cx)
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IVUS catheter for valid assessment.39 Current clinical
OCT systems provide efficient tools to check for under-
expanded lumen and stent.40 The occurrence of stent
and vessel underexpansion may be reduced by post-
dilatation, but modifying fibrocalcified plaques sufficient-
ly before implanting the stents may be as important.37
The cutoff values for minimal stent area proposed by
Kang et al were derived by IVUS and may not directly
apply to OCT. In OCTOBER, a minimal stent diameter
larger than 90% of the segmental reference size is
required and is in line with expansion limits of the
ILUMIEN III trial. The POT41 is of particular importance
to ensure tapering of the vessel and to improve stent
apposition and opening the SB ostium for facilitated
rewiring. Downsides to POT may relate to (1) cases
where the lesion is uncovered proximally and a POT
balloon extends into the lesion (“geographical miss”) and
(2) the final POT. In performing POT after SB treatment
(balloon inflation or stent implantation), a position of the
POT balloon across the SB takeoff may push the carina
and carinal struts toward the SB ostium, and in Y-shaped
bifurcation, the area of the SB ostium might be reduced.
Thus, final POT is optional in OCTOBER, and if
performed, the balloon should not cross the SB takeoff.
The rePOT technique (or POT-side-POT) could have
similar disadvantages in distorting the bifurcation core
segment and is not allowed in OCTOBER because of
limited documentation for its clinical benefit. The OCT
guiding strategy applied in the present study includes
OCT sizing of length and diameter of both the stent and
the POT balloon. The stent landing zone is extended
proximally to accommodate the full POT balloon length if
possible.
Tu et al (2013) reported that, in 40% of cases, it was not
possible to achieve the optimal angiographic projection
angle for the ostium of the Cx due to the restraints of the
C-arm of the angiographic equipment.4 In these cases, a
short Cx stenosis or a tight ostial part of a longer Cx stenosis
is not visualized, and by that, a systematic intravascular
imaging evaluation is needed. Still, Mintz and colleagues
(2011) showed that IVUSwas not reliable for assessment of
the Cx ostium from a main vessel pullback.39 The side
branch OCT study by Karanasos et al42 proved that OCT
was capable of providing accurate assessments of the SB
ostium from both MV and SB pullbacks.
Malapposition
Malapposition is a frequent finding in case-control studies
of stent thrombosis,43,44 but in the published observational
trials, it has not been possible to identify acute malapposi-
tion as a predictor of clinical events.18,45,46 This might
relate to the rather low patient numbers and a low- to
medium-risk population. Despite the lack of robust
evidence, it is still reasonable to aim for full stent apposition
for the following reasons: (1) stent strut coverage is delayedon malapposed struts,47 and uncovered struts are associ-
ated to stent thrombosis44; (2) malapposed struts may
directly increase the risk of ST,44 asmalapposition results in
high shear stress rate on the strut surface, known to
activate platelets and coagulation cascade36; and (3)
accidental abluminal rewiring occurs only in the presence
of malapposition and is a prominent risk in bifurcation
treatment when rewiring through already implanted stents
(see below).7 Malapposition at 6-month follow-up can be
reduced by index procedure OCT guiding,21 so an active
approach may be feasible and effective.
Wire position
Modeling studies by Foin et al48 and clinical studies by
Alegría-Barrero et al49 showed that wire positions in
recrossing side branches critically affected scaffolding of
the side branch ostium and the extent of stent strut
malapposition at the bifurcation. Risk of stent malapposi-
tion was also increased with complex stenting tech-
niques.50,51 Wire positions can be evaluated and
optimized by OCT guiding52,53; thus, in the OCTOBER
trial, we aim for optimal wire position in stent cell
recrossing. This means recrossing near the carina point
but in 2-stent techniques with the provision that rewiring
in extreme positions may increase the risk of abluminal
rewiring of the stent in the jailed branch and should be
avoided in such cases.54,55 Bench studies by Murasato et
al (2009) showed examples of accidentally crushed stents
due to abluminal rewiring during complex treatment.54
This risk was later confirmed by Zhang et al and Würtz et
al.8,56 The latter reported clinical events where accidental
crushed segments were identified by OCT but were not
visible during the index procedure by angiography.
Similar findings by Abdou et al57 showed that angiogra-
phy is ambiguous in guiding complex stenting in the left
main bifurcation. In the OCTOBER trial, we aim for early
full stent apposition to reduce the risk of abluminal
rewiring, and an OCT acquisition after rewiring is
mandatory for excluding abluminal rewiring and evaluat-
ing multiple other factors at that step.
OCT for guiding LMCA bifurcation stenting
Fujino et al reported that guiding LMCA stenting by
OCT was feasible, was safe, and provided superior
information on stent position compared to IVUS but
was limited in ostial LMCA assessment.6 Burzotta et al
confirmed that OCT evaluation was feasible in midshaft
and distal LMCA lesions.13Optimization of nonbifurcation stent implants
In cases where multiple lesion require stent implanta-
tion, the OCT guiding protocol is applied to all lesions
including lesions treated in staged procedures. The
degree of revascularization follows present guidelines.
This patient-oriented optimization of all target lesions is
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includes nonbifurcation target lesions. It is expected that
OCT guiding has a positive yet smaller effect on outcome
in less complex lesions. Furthermore, as autopsy rates
remain very low, cardiac death can rarely be related to
target or nontarget lesions. Isolated outcomes for target
bifurcations are reported in secondary end points.
Limiting use of contrast
Several aspects of the design are aimed to limit the
additional use of contrast in the OCT arm. This includes
(1) study training in acquisition technique to identify
optimal guiding catheter positions before injection, (2)
optimal timing of OCT scans for each stent technique, (3)
use of fast pullback speed requiring 10 mL contrast or less
per pullback, and (4) simultaneous cining during pullback
for use as regular angiographic acquisition and optional
OCT to angiography co-registration. Patients with severe
renal disease are not enrolled in the trial.
Improve clinical outcome in complex PCI
Complex bifurcation lesions require treatment by
complex stenting techniques with an elevated risk of
suboptimal treatment results. OCT enables improved
procedural control over correctable factors that may lead
to optimized implantation results. Whether systematic
use of OCT to optimize complex bifurcation stenting
improves clinical outcome using best-in-class DES re-
mains unknown but is highly likely based on the multiple
reports described above.
Conclusion
OCTOBER is the first adequately powered clinical trial
aimed to show if routine OCT guiding of stent
implantation improves clinical outcome. A positive
outcome may establish OCT as a routine tool for
optimization of complex PCI, whereas a negative result
would indicate that OCT remains a tool for ad hoc
evaluation in select cases.
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